Patients | 106 |
Age years | 5 (3–8) |
Male | 62 (58) |
Ethnicity | |
Caucasian | 66 (62) |
North African | 21 (20) |
Black | 4 (4) |
Asian | 3 (3) |
East Indian | 3 (3) |
Hispanic | 3 (3) |
Interracial/others | 6 (6) |
Medical history in past year | |
Patients with ≥1 acute care visit | 63 (59) |
Patients with ≥1 hospital admission | 16 (15) |
Medication prescribed at index visit | |
Montelukast | 106 (100) |
Dose (n=104) | |
4 mg | 53 (51) |
5 mg | 47 (45) |
10 mg | 4 (4) |
Formulation# (n=55) | |
Chewable tablet | 52 (95) |
Granules | 2 (4) |
Tablet | 1 (2) |
ICS | 61 (58) |
LABA | 15 (14) |
Physician assessment at index visit | |
Asthma symptoms (n=100) | |
Persistent | 83 (83) |
Episodic | 17 (17) |
Unclear | 0 (0) |
Trigger pattern (n=93) | |
Single trigger | 16 (17) |
Multiple trigger | 77 (83) |
Physician's assessment of asthma control (n=103) | |
Excellent | 10 (10) |
Good | 52 (50) |
Unsatisfactory | 28 (27) |
Poor | 13 (13) |
Atopy¶ | 32 (30) |
Child's predisposing conditions | |
Any | 39 (37) |
Migraine | 3 (3) |
Attention deficit disorder | 21 (20) |
Depression | 1 (1) |
Anxiety | 11 (10) |
Autism | 4 (4) |
Sleep disorder | 6 (6) |
Learning disabilities | 1 (1) |
Family predisposing conditions+ | |
Any | 59 (56) |
Migraine | 40 (38) |
Behavioural problems | 15 (14) |
Sleep disorders | 18 (17) |
Psychological or psychiatric disorders | 17 (16) |